Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Isavuconazole: Case Report and Pharmacokinetic Considerations.

Marchesi F, Girmenia C, Goffredo BM, Salvatorelli E, Romano A, Mengarelli A, Minotti G, Menna P.

Chemotherapy. 2018 Nov 20;63(5):253-256. doi: 10.1159/000494329. [Epub ahead of print]

PMID:
30458443
2.

The Endogenous Lusitropic and Chronotropic Agent, B-Type Natriuretic Peptide, Limits Cardiac Troponin Release in Cancer Patients with an Early Impairment of Myocardial Relaxation Induced by Anthracyclines.

Menna P, Salvatorelli E, Armento G, Annibali O, Greco C, Marchesi F, Calabrese V, Reggiardo G, Minotti G.

J Pharmacol Exp Ther. 2018 Dec;367(3):518-527. doi: 10.1124/jpet.118.253104. Epub 2018 Oct 1.

PMID:
30275150
3.

Pharmacology of Cardio-Oncology: Chronotropic and Lusitropic Effects of B-Type Natriuretic Peptide in Cancer Patients with Early Diastolic Dysfunction Induced by Anthracycline or Nonanthracycline Chemotherapy.

Menna P, Calabrese V, Armento G, Annibali O, Greco C, Salvatorelli E, Marchesi F, Reggiardo G, Minotti G.

J Pharmacol Exp Ther. 2018 Jul;366(1):158-168. doi: 10.1124/jpet.118.249235. Epub 2018 May 2.

PMID:
29720563
4.

Relevance of small GTPase Rac1 pathway in drug and radio-resistance mechanisms: Opportunities in cancer therapeutics.

Cardama GA, Alonso DF, Gonzalez N, Maggio J, Gomez DE, Rolfo C, Menna PL.

Crit Rev Oncol Hematol. 2018 Apr;124:29-36. doi: 10.1016/j.critrevonc.2018.01.012. Epub 2018 Feb 4. Review.

PMID:
29548483
5.

Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study.

Calabrese V, Menna P, Annibali O, Armento G, Carpino A, Cerchiara E, Greco C, Marchesi F, Spallarossa P, Toglia G, Reggiardo G, Minotti G; Collaborators.

Chemotherapy. 2018;63(2):55-63. doi: 10.1159/000486761. Epub 2018 Feb 9. Erratum in: Chemotherapy. 2018 Apr 10;63(2):64.

PMID:
29428939
6.

Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy.

Menna P, Salvatorelli E, Mattei A, Cappiello D, Minotti G, Carassiti M.

Chemotherapy. 2018;63(1):35-38. doi: 10.1159/000484974. Epub 2017 Dec 22.

7.

Pharmacological Rac1 inhibitors with selective apoptotic activity in human acute leukemic cell lines.

Cabrera M, Echeverria E, Lenicov FR, Cardama G, Gonzalez N, Davio C, Fernández N, Menna PL.

Oncotarget. 2017 Oct 4;8(58):98509-98523. doi: 10.18632/oncotarget.21533. eCollection 2017 Nov 17.

8.

Low-Dose Anthracycline and Risk of Heart Failure in a Pharmacokinetic Model of Human Myocardium Exposure: Analog Specificity and Role of Secondary Alcohol Metabolites.

Salvatorelli E, Menna P, Chello M, Covino E, Minotti G.

J Pharmacol Exp Ther. 2018 Feb;364(2):323-331. doi: 10.1124/jpet.117.246140. Epub 2017 Dec 8.

PMID:
29222131
9.

Rho GTPases as therapeutic targets in cancer (Review).

Cardama GA, Gonzalez N, Maggio J, Menna PL, Gomez DE.

Int J Oncol. 2017 Oct;51(4):1025-1034. doi: 10.3892/ijo.2017.4093. Epub 2017 Aug 9. Review.

10.

Cancer drugs and QT prolongation: weighing risk against benefit.

Menna P, Salvatorelli E, Minotti G.

Expert Opin Drug Saf. 2017 Oct;16(10):1099-1102. doi: 10.1080/14740338.2017.1354987. Epub 2017 Jul 20. No abstract available.

PMID:
28699784
11.

Phylogenies of symbiotic genes of Bradyrhizobium symbionts of legumes of economic and environmental importance in Brazil support the definition of the new symbiovars pachyrhizi and sojae.

Delamuta JRM, Menna P, Ribeiro RA, Hungria M.

Syst Appl Microbiol. 2017 Jul;40(5):254-265. doi: 10.1016/j.syapm.2017.04.005. Epub 2017 Jun 7.

PMID:
28647304
12.

Modeling Human Myocardium Exposure to Doxorubicin Defines the Risk of Heart Failure from Low-Dose Doxorubicin.

Salvatorelli E, Menna P, Chello M, Covino E, Minotti G.

J Pharmacol Exp Ther. 2017 Aug;362(2):263-270. doi: 10.1124/jpet.117.242388. Epub 2017 May 30.

13.

Do You Know Pixantrone?

Minotti G, Menna P, Salvatorelli E.

Chemotherapy. 2017;62(3):192-193. doi: 10.1159/000464276. Epub 2017 Mar 24. No abstract available.

14.

Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief Overview.

Menna P, Salvatorelli E.

Chemotherapy. 2017;62(3):159-168. doi: 10.1159/000455823. Epub 2017 Jan 26.

15.

Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells.

Gonzalez N, Cardama GA, Comin MJ, Segatori VI, Pifano M, Alonso DF, Gomez DE, Menna PL.

Cell Signal. 2017 Jan;30:154-161. doi: 10.1016/j.cellsig.2016.12.002. Epub 2016 Dec 7.

PMID:
27939839
16.

Rethinking Drugs from Chemistry to Therapeutic Opportunities: Pixantrone beyond Anthracyclines.

Menna P, Salvatorelli E, Minotti G.

Chem Res Toxicol. 2016 Aug 15;29(8):1270-8. doi: 10.1021/acs.chemrestox.6b00190. Epub 2016 Jul 22.

PMID:
27420111
17.

Managing anthracycline-induced cardiotoxicity: beginning with the end in mind.

Salvatorelli E, Menna P, Minotti G.

Future Cardiol. 2015 Jul;11(4):363-6. doi: 10.2217/FCA.15.35. Epub 2015 Aug 4. No abstract available.

PMID:
26239550
18.

The concomitant management of cancer therapy and cardiac therapy.

Salvatorelli E, Menna P, Cantalupo E, Chello M, Covino E, Wolf FI, Minotti G.

Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2727-37. doi: 10.1016/j.bbamem.2015.01.003. Epub 2015 Jan 14. Review.

19.

Proapoptotic and antiinvasive activity of Rac1 small molecule inhibitors on malignant glioma cells.

Cardama GA, Gonzalez N, Ciarlantini M, Gandolfi Donadío L, Comin MJ, Alonso DF, Menna PL, Gomez DE.

Onco Targets Ther. 2014 Oct 30;7:2021-33. doi: 10.2147/OTT.S67998. eCollection 2014.

20.

Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship.

Menna P, Gallo P, Vespasiani Gentilucci U, Salvatorelli E, Galati G, Minotti G, Picardi A.

J Viral Hepat. 2014 Oct;21(10):e136-7. doi: 10.1111/jvh.12264. Epub 2014 Jun 16. No abstract available.

PMID:
24935352
21.

Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox.

Cacciapaglia F, Salvatorelli E, Minotti G, Afeltra A, Menna P.

Cardiovasc Toxicol. 2014 Dec;14(4):387-92. doi: 10.1007/s12012-014-9257-z.

PMID:
24798036
22.

Preclinical development of novel Rac1-GEF signaling inhibitors using a rational design approach in highly aggressive breast cancer cell lines.

Cardama GA, Comin MJ, Hornos L, Gonzalez N, Defelipe L, Turjanski AG, Alonso DF, Gomez DE, Menna PL.

Anticancer Agents Med Chem. 2014;14(6):840-51.

23.

Genomic basis of broad host range and environmental adaptability of Rhizobium tropici CIAT 899 and Rhizobium sp. PRF 81 which are used in inoculants for common bean (Phaseolus vulgaris L.).

Ormeño-Orrillo E, Menna P, Almeida LG, Ollero FJ, Nicolás MF, Pains Rodrigues E, Shigueyoshi Nakatani A, Silva Batista JS, Oliveira Chueire LM, Souza RC, Ribeiro Vasconcelos AT, Megías M, Hungria M, Martínez-Romero E.

BMC Genomics. 2012 Dec 27;13:735. doi: 10.1186/1471-2164-13-735.

24.

The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.

Salvatorelli E, Menna P, Paz OG, Chello M, Covino E, Singer JW, Minotti G.

J Pharmacol Exp Ther. 2013 Feb;344(2):467-78. doi: 10.1124/jpet.112.200568. Epub 2012 Nov 28.

25.

Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis.

Salvatorelli E, De Tursi M, Menna P, Carella C, Massari R, Colasante A, Iacobelli S, Minotti G.

Drug Metab Dispos. 2012 Dec;40(12):2365-73. doi: 10.1124/dmd.112.047480. Epub 2012 Sep 12.

26.

Telomere structure and telomerase in health and disease (review).

Gomez DE, Armando RG, Farina HG, Menna PL, Cerrudo CS, Ghiringhelli PD, Alonso DF.

Int J Oncol. 2012 Nov;41(5):1561-9. doi: 10.3892/ijo.2012.1611. Epub 2012 Aug 29. Review.

27.

Multilocus sequence analysis (MLSA) of Bradyrhizobium strains: revealing high diversity of tropical diazotrophic symbiotic bacteria.

Delamuta JR, Ribeiro RA, Menna P, Bangel EV, Hungria M.

Braz J Microbiol. 2012 Apr;43(2):698-710. doi: 10.1590/S1517-83822012000200035. Epub 2012 Jun 1.

28.

Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin.

Salvatorelli E, Menna P, Gonzalez Paz O, Surapaneni S, Aukerman SL, Chello M, Covino E, Sung V, Minotti G.

J Pharmacol Exp Ther. 2012 May;341(2):474-83. doi: 10.1124/jpet.111.190264. Epub 2012 Feb 15.

29.

Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin.

Salvatorelli E, Menna P, Surapaneni S, Aukerman SL, Chello M, Covino E, Sung V, Minotti G.

J Pharmacol Exp Ther. 2012 May;341(2):464-73. doi: 10.1124/jpet.111.190256. Epub 2012 Feb 15.

30.

Anthracycline cardiotoxicity.

Menna P, Paz OG, Chello M, Covino E, Salvatorelli E, Minotti G.

Expert Opin Drug Saf. 2012 May;11 Suppl 1:S21-36. doi: 10.1517/14740338.2011.589834. Epub 2011 Jun 2. Review.

PMID:
21635149
31.

Matters of the heart: the case of TNFalpha-targeting drugs.

Cacciapaglia F, Menna P, Navarini L, Afeltra A, Salvatorelli E, Minotti G.

Mol Interv. 2011 Apr;11(2):79-87. doi: 10.1124/mi.11.2.4. No abstract available.

PMID:
21540466
32.

Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues.

Cacciapaglia F, Navarini L, Menna P, Salvatorelli E, Minotti G, Afeltra A.

Autoimmun Rev. 2011 Aug;10(10):631-5. doi: 10.1016/j.autrev.2011.04.014. Epub 2011 Apr 22. Review.

PMID:
21539939
33.
34.

Pharmacological foundations of cardio-oncology.

Minotti G, Salvatorelli E, Menna P.

J Pharmacol Exp Ther. 2010 Jul;334(1):2-8. doi: 10.1124/jpet.110.165860. Epub 2010 Mar 24.

35.

Anthracycline degradation in cardiomyocytes: a journey to oxidative survival.

Menna P, Salvatorelli E, Minotti G.

Chem Res Toxicol. 2010 Jan;23(1):6-10. doi: 10.1021/tx9003424.

PMID:
19954191
36.

Phylogeny and taxonomy of a diverse collection of Bradyrhizobium strains based on multilocus sequence analysis of the 16S rRNA gene, ITS region and glnII, recA, atpD and dnaK genes.

Menna P, Barcellos FG, Hungria M.

Int J Syst Evol Microbiol. 2009 Dec;59(Pt 12):2934-50. doi: 10.1099/ijs.0.009779-0. Epub 2009 Jul 23.

PMID:
19628593
37.

4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.

Menna P, Salvatorelli E, Minotti G.

Chem Res Toxicol. 2009 Jun;22(6):978-83. doi: 10.1021/tx900039p.

PMID:
19397277
38.

rep-PCR fingerprinting and taxonomy based on the sequencing of the 16S rRNA gene of 54 elite commercial rhizobial strains.

Binde DR, Menna P, Bangel EV, Barcellos FG, Hungria M.

Appl Microbiol Biotechnol. 2009 Jul;83(5):897-908. doi: 10.1007/s00253-009-1927-6. Epub 2009 Mar 17.

PMID:
19290521
39.

Novel genes related to nodulation, secretion systems, and surface structures revealed by a genome draft of Rhizobium tropici strain PRF 81.

Pinto FG, Chueire LM, Vasconcelos AT, Nicolás MF, Almeida LG, Souza RC, Menna P, Barcellos FG, Megías M, Hungria M.

Funct Integr Genomics. 2009 May;9(2):263-70. doi: 10.1007/s10142-009-0109-z. Epub 2009 Jan 29.

PMID:
19184146
40.

Doxorubicinolone formation and efflux: a salvage pathway against epirubicin accumulation in human heart.

Salvatorelli E, Menna P, Lusini M, Covino E, Minotti G.

J Pharmacol Exp Ther. 2009 Apr;329(1):175-84. doi: 10.1124/jpet.108.149260. Epub 2009 Jan 14.

41.

Enhanced cytostatic activity of statins in mouse mammary carcinoma cells overexpressing β2-chimaerin.

Menna PL, Parera RL, Cardama GA, Alonso DF, Gomez DE, Farina HG.

Mol Med Rep. 2009 Jan-Feb;2(1):97-102. doi: 10.3892/mmr_00000068.

PMID:
21475797
42.

Genetic differences between Bradyrhizobium japonicum variant strains contrasting in N(2)-fixation efficiency revealed by representational difference analysis.

Barcellos FG, Batista JS, Menna P, Hungria M.

Arch Microbiol. 2009 Feb;191(2):113-22. doi: 10.1007/s00203-008-0432-0. Epub 2008 Oct 15.

PMID:
18854979
43.

Cardiotoxicity of antitumor drugs.

Menna P, Salvatorelli E, Minotti G.

Chem Res Toxicol. 2008 May;21(5):978-89. doi: 10.1021/tx800002r. Epub 2008 Apr 1.

PMID:
18376852
44.

Anthracycline cardiotoxicity.

Menna P, Salvatorelli E, Gianni L, Minotti G.

Top Curr Chem. 2008;283:21-44. doi: 10.1007/128_2007_11.

PMID:
23605627
45.

An introduction to the metabolic determinants of anthracycline cardiotoxicity.

Menna P, Recalcati S, Cairo G, Minotti G.

Cardiovasc Toxicol. 2007;7(2):80-5. Review.

PMID:
17652809
46.

Doxorubicin degradation in cardiomyocytes.

Menna P, Salvatorelli E, Minotti G.

J Pharmacol Exp Ther. 2007 Jul;322(1):408-19. Epub 2007 Apr 27.

48.

Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies.

Salvatorelli E, Menna P, Gianni L, Minotti G.

J Pharmacol Exp Ther. 2007 Feb;320(2):790-800. Epub 2006 Nov 29.

49.

In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity.

Menna P, Minotti G, Salvatorelli E.

Cell Biol Toxicol. 2007 Jan;23(1):49-62. Epub 2006 Oct 9. Review.

PMID:
17031515
50.

Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies.

Salvatorelli E, Menna P, Cascegna S, Liberi G, Calafiore AM, Gianni L, Minotti G.

J Pharmacol Exp Ther. 2006 Jul;318(1):424-33. Epub 2006 Apr 13.

Supplemental Content

Support Center